ADvocate trials: 52-week results

Key messages

• Lebrikizumab selectively binds to IL-13 with high affinity, targeting and neutralizing signaling.
• The ADvocate trials demonstrated robust efficacy, which was maintained through 52 weeks.
• Q4W dosing provided similar clinical responses to Q2W.
• Most patients did not require topical rescue therapy.
• The safety profile was consistent with previously published data.